Developing long-acting local drug delivery for hereditary hair loss
Androgenetic alopecia causes progressive hair thinning and can affect confidence and quality of life. Existing drug treatments may require frequent, sustained use, and exposure outside the scalp can raise safety concerns that discourage some people from starting or continuing treatment.
aevX Bio is developing AV-1, a long-acting local treatment for androgenetic alopecia. Its preclinical approach aims to sustain delivery of androgen-modulating drugs in the scalp, supporting hair-loss treatment while limiting exposure elsewhere in the body.
What stands out about aevX Bio
aevX Bio registered a capital increase involving 176,000 pre-seed preferred shares in May 2026.
Co-founder Julien Grogg led first-in-human work at MaxiVAX and later served as COO and CEO of Release Therapeutics.
Co-founder Julien Grogg earned a Paris-Saclay doctorate for developing encapsulated-cell technology to sustain delivery of therapeutic proteins.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.